

---

# S&P TEST

SWOT & PESTLE.com

---

## CHUGAI PHARMACEUTICAL CO. LTD. SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email [support@swotandpestle.com](mailto:support@swotandpestle.com).

**Company Name :** Chugai Pharmaceutical Co. Ltd.

**Company Sector :** Pharmaceutical

**Operating Geography :** Japan, Asia, Global

**About the Company :**

Chugai Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company. It is a subsidiary of Hoffmann-La Roche, which controls 62 per cent of the firm and is based in Tokyo. Chugai was founded in 1925 and has since updated its business management by constructing research facilities and plants, as well as contributing to healthcare in Japan and overseas through a variety of goods. The company researches and develops treatments for bone and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain ailments. Neutrogen addresses white blood cell loss induced by chemotherapy; Epogin treats red blood cell loss caused by chronic renal failure; Sigmart, an antianginal drug; and Alfarol for osteoporosis are some of the products offered by the firm. Through subsidiaries and branch locations, Chugai Pharmaceuticals has operations in Asia, Europe, and North America. On May 10th, 2022, the company announced that it will extend its commitment to the World Federation of Hemophilia Humanitarian Aid Program until 2028, in collaboration with Roche.

Chugai Pharmaceutical's USP or unique selling proposition is that it is the pioneer in next-generation personalised healthcare (PHC), with strong collaborations with Roche to ensure that novel treatments are generally accessible. The mission statement of Chugai reads, " to create innovative drugs for the benefit of patients".

**Revenue :**

JP ¥ 804.7 billion - FY ending 31st March 2021

JP ¥ 786.9 billion - FY ending 31st March 2020

**SWOT Analysis :**

The SWOT Analysis for Chugai Pharmaceutical Co. Ltd. is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> <li>1.Strategic partnership with Roche</li> <li>2.Strong consistent financial performance creating value for its shareholders</li> <li>3.World class technologies providing competitive advantages</li> <li>4.Rich product portfolio with 54 pipeline projects</li> <li>5.Recognized market leader amongst healthcare professionals</li> </ul>	<ul style="list-style-type: none"> <li>1.High dependence on Japanese market for its revenue</li> <li>2.Over reliance on Roche causing, it to lose its independence</li> </ul>
Opportunities	Threats
<ul style="list-style-type: none"> <li>1.Growing pharmaceutical market globally</li> <li>2.Development of API manufacturing unit to strengthen its production capabilities</li> <li>3.Opportunity to increase revenue with newly developed products</li> <li>4.Drug approvals can help increase market share</li> </ul>	<ul style="list-style-type: none"> <li>1.Development of new disruptive technology or solution</li> <li>2.Change in terms of alliance with Roche</li> <li>3.Rising Covid-19 cases can affect company operations</li> </ul>

## PESTLE Analysis :

The PESTLE Analysis for Chugai Pharmaceutical Co. Ltd. is given below:

<p style="text-align: center;"><b>Political</b></p> <p>1. Amendment of Pharmaceuticals and Medical devices (PMD) Act</p> <p>2. Japan lowering drug costs to make it more affordable</p>	<p style="text-align: center;"><b>Economical</b></p> <p>1. Stagnation of Japanese economy can hinder company growth</p> <p>2. Rising medical cost in Japan</p>
<p style="text-align: center;"><b>Social</b></p> <p>1. Aging Japanese population to increase demand</p> <p>2. Shrinking Japanese population can create downward drag on company sales</p>	<p style="text-align: center;"><b>Technological</b></p> <p>1. Introduction of Digital biomarkers to analyse outcome of drug treatment</p> <p>2. Utilization of AI for drug discovery</p>
<p style="text-align: center;"><b>Legal</b></p> <p>1. Infringement of IP rights by competitor</p> <p>2. Settlement of dispute against Chugai</p>	<p style="text-align: center;"><b>Environmental</b></p> <p>1. Positively driven CSR activities for environmental change</p>

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Chugai Pharmaceutical Co. Ltd.** SWOT & PESTLE Analysis is a paid report at **27 U.S.D.**



\* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



# S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

# Copyright Notice

The information provided in the SWOT and PESTLE research reports on [www.swotandpestle.com](http://www.swotandpestle.com) are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2023 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:  
[support@swotandpestle.com](mailto:support@swotandpestle.com)